UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC.,

and

LUPIN LTD. and LUPIN PHARMACEUTICALS, INC. Petitioners,

v.

HORIZON THERAPEUTICS, INC., Patent Owner.

Case IPR2015-01117¹ Patent 8,642,012

PETITIONER'S UPDATED EXHIBIT LIST

Mail Stop "PATENT BOARD"

Patent Trial and Appeal Board
U.S. Patent and Trademark Office

P.O. Box 1450 Alexandria, VA 22313-1450

¹ Case IPR2015-00283, instituted on a petition filed by Lupin Ltd. and Lupin Pharmaceuticals, Inc., has been joined with this proceeding.



Pursuant to 37 C.F.R. § 42.63(e), the Petitioner hereby provides an updated exhibit list:

Exhibit #	Description
1001	U.S. Patent No. 8,642,012 to Scharschmidt ("the '012 patent), filed January 7, 2009, issued February 4, 2014.
1002	Declaration of Dr. Neal Sondheimer.
1003	Curriculum vitae of Dr. Neal Sondheimer.
1004	Reserved.
1005	Simell, et al., Waste Nitrogen Excretion Via Amino Acid Acylation: Benzoate and Phenylacetate in Lysinuric Protein Intolerance, 20 Pediatric Research, 1117–1121 (1986). ("Simell").
1006	Reserved.
1007	Reserved.
1008	Reserved.
1009	Reserved.
1010	Reserved.
1011	Fernandes, Saudubray Berghe (editors), <i>Inborn Metabolic Diseases Diagnosis and Treatment</i> , 219–220 (3d ed. 2000). ("Fernandes").
1012	Brusilow, <i>Phenylacetylglutamine May Replace Urea as a Vehicle for Waste Nitrogen Excretion</i> , 29 Pediatric Research, 147–150 (1991). ("Brusilow '91").
1013	Reserved.



Exhibit #	Description
1014	Reserved.
1015	Kasumov, et al., New Secondary Metabolites of Phenylbutyrate in Humans and Rats, 32 Drug Metabolism and Disposition, 10–19 (2004). ("Kasumov").
1016	Sherwin, et al., The Maximum Production of Glutamine by the Human Body as Measured by the Output of Phenylacetylglutamine, 37 J. Biol. Chem., 113–119 (1919). ("Sherwin").
1017	Shiple, et al, Synthesis of Amino Acids in Animal Organisms. I. Synthesis of Glycocoll and Glutamine in the Human Organism, 44 J. American Chem. Society, 618–624 (1922). ("Shiple").
1018	U.S. Patent No. 4,284,647 to Brusilow et al., filed March 31, 1980, issued August 18, 1981 ("the '647 patent").
1019	Reserved.
1020	Reserved.
1021	Prosecution History of the '012 patent.
1022	Joint Claim Construction filed March 13, 2015 in Eastern District of Texas District Court, Case 2:14-cv-00384.
1023	Piscitelli, et al., <i>Disposition of Phenylbutyrate and its Metabolites, Phenylacetate and Phenylacetylglutamine</i> , 35 J. Clin. Pharmacol., 368–373 (1995). ("Piscitelli").
1024	Reserved.
1025	Comte, et al., <i>Identification of phenylbutyrylglutamine, a new metabolite of phenylbutyrate metabolism in humans</i> , 37 J. Mass. Spectrom. 581–90 (2002). ("Comte").



Exhibit #	Description
1026	U.S. Patent No. 5,968,979 to Brusilow, filed Feb. 7, 1995, issued Oct. 19, 1999 ("the '979 patent").
1027	Collins et al., <i>Oral Sodium Phenylbutyrate Therapy in Homozygous β Thalassemia: A Clinical Trial</i> , 85 Blood 43 (1995). ("Collins").
1028	Declaration of Barry Gilman.
1029	Declaration of Dr. Neal Sondheimer, Ex. 1002 previously filed in IPR2015-01117. (Deposition Exhibit, Not Filed)
1030	Declaration of Dr. Neal Sondheimer, Ex. 1002 previously filed in IPR2015-01127. (Deposition Exhibit, Not Filed)
1031	Current curriculum vitae of Dr. Neal Sondheimer, prepared January 23, 2016. (Deposition Exhibit, Not Filed)
1032	API website printout re sodium phenylbutyrate. (Deposition Exhibit, Not Filed)
1033	Deardorff, M. et al., Complex Management of a Patient with a Contiguous Xp11.4 Gene Deletion Involving Ornithine Transcarbamylase: A Role for Detailed Molecular Analysis in Complex Presentations of Classical Diseases, 94(4) Mol. Genet. Metab. 498-502 (2008). (Deposition Exhibit, Not Filed)
1034	Petitioner's Objections Under 37 C.F.R. § 42.62 to Evidence Submitted by Patent Owner, served in IPR2015-01117 on April 4, 2016.
1035	Reserved.
1036	Email from E. Simic to A. Burgy et al., re: IPR-2015-01117 and 01127



Exhibit #	Description
1037	Dawson-Saunders, B. et al., Basic & Clinical Biostatistics, 46 (Appelton & Lange, 2d ed. 1994).
1038	Reserved.
1039	Mokhtarani, M. et al., Elevated Phenylacetic Acid Levels Do Not Correlate With Adverse Events In Patients With Urea Cycle Disorders Or Hepatic Encephalopathy And Can Be Predicted Based On The Plasma PAA To PAGN Ratio, 110(4) Mol. Genet. Metab. 446-453 (2013).
1040	Kingsbury, F. et al., A Rapid Method for the Determination of Hippuric Acid in Urine, 48 J. Biol. Chem. 13-20 (1921)

Date: June 14, 2016

Axinn, Veltrop & Harkrider LLP

950 F Street, N.W.

Washington, DC 20004

Tel: (202) 912-4700

Respectfully Submitted,

Aziz Burgy

Registration No. 51,514 *Attorney for Petitioner*

Par Pharmaceutical, Inc.



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

